本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Recursion Pharmaceuticals, Inc.

4.14
-0.1900-4.39%
盘前4.220.0800+1.93%04:40 EST
成交量:3,141.54万
成交额:1.33亿
市值:21.55亿
市盈率:-2.32
高:4.38
开:4.17
低:4.13
收:4.33
52周最高:12.36
52周最低:3.79
股本:5.21亿
流通股本:4.15亿
量比:0.98
换手率:7.57%
股息:- -
股息率:- -
每股收益(TTM):-1.7839
每股收益(LYR):-1.6909
净资产收益率:-91.06%
总资产收益率:-42.20%
市净率:2.06
市盈率(LYR):-2.45

数据加载中...

2025/11/05

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/11/05

重要事件披露

Form 8-K - Current report
2025/11/04

关联方拟减持公告

Form 144 | RECURSION PHARMACEUTICALS高管Christopher Gibson拟减持40000股,总价约208400美元
2025/10/29

重要事件披露

Form 8-K - Current report
2025/10/23

关联方拟减持公告

Form 144 | Recursion Pharmaceuticals高管 Gibson拟减持100000股,总价约57万美元
2025/10/10

关联方拟减持公告

Form 144 | Recursion Pharmaceuticals高管 Christopher Gibson拟减持100,000股,总价约60.4万美元
2025/09/25

关联方拟减持公告

Form 144 | Recursion Pharmaceuticals高管 Gibson 拟减持10万股,总价约47.6万美元
2025/09/10

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/08/29

重要事件披露

Form 8-K/A - Current report: [Amend]
2025/08/26

关联方拟减持公告

Form 144 | Recursion Pharmaceuticals高管 Gibson拟减持10万股,总价约48.4万美元
2025/08/18

关联方拟减持公告

Form 144 | Recursion Pharmaceuticals高管 Khan Najat拟减持36599股,总价约20.2万美元
2025/08/11

关联方拟减持公告

Form 144 | Recursion Pharmaceuticals 高管 Christopher Gibson 拟减持617875股,总价约326.2万美元
2025/08/05

重要事件披露

Form 8-K - Current report
2025/08/05

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/07/08

重要事件披露

Form 8-K - Current report
2025/06/18

重要事件披露

Form 8-K - Current report
2025/06/10

重要事件披露

Form 8-K - Current report
2025/05/09

重要事件披露

Form 8-K - Current report
2025/05/05

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/05/05

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]